This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gales, A. C.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gales, A. C.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2001, p. 183-190, Vol. 39, No. 1
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.1.183-190.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines

Ana C. Gales,1,2 Adriana O. Reis,2 and Ronald N. Jones1,*

Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242,1 and Disciplina de Doenças Infecciosas e Parasitàrias, Universidade Federal de São Paulo, São Paulo, Brazil2

Received 29 June 2000/Returned for modification 4 September 2000/Accepted 16 October 2000

The emergence of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. has necessitated the search for alternative parenteral agents such as the polymyxins. The National Committee for Clinical Laboratory Standards (NCCLS) documents do not currently provide interpretative criteria for the testing of the polymyxins, colistin and polymyxin B. Therefore, an evaluation of the antimicrobial activity of colistin and polymyxin B was initiated using 200 bloodstream infection pathogens collected through the SENTRY Antimicrobial Surveillance Program. All susceptibility tests were performed according to the NCCLS recommendations. Polymyxin B and colistin displayed a nearly identical spectrum of activity, exhibiting excellent potency against P. aeruginosa (MIC90, 2 µg/ml) and Acinetobacter sp. (MIC90, 2 µg/ml). In contrast, they showed limited activity against some other nonfermentative bacilli such as Burkholderia cepacia (MIC90, >= 128 µg/ml). Excellent correlation was achieved between broth microdilution and agar dilution tests (r = 0.96 to 0.98); 94.3% of the results were ±1 log2 dilution between the methods used for both compounds. At a resistance breakpoint of >= 4 µg/ml for both agents, unacceptable false-susceptible or very major errors were noted for colistin (5%) and polymyxin B (6%). Modified zone criteria for colistin (<= 11 and >= 14 mm) and polymyxin B (<= 10 and >= 14 mm) were suggested, but some degree of error persisted (>= 3.5%). It is recommended that all susceptible disk diffusion results be confirmed by MIC tests using the preferred reference NCCLS method. The quality control (QC) ranges listed in the product package insert require an adjusted range by approximately 3 mm for both NCCLS gram-negative quality control strains. This evaluation of in vitro susceptibility test methods for the polymyxin class drugs confirmed continued serious testing error with the disk diffusion method, the possible need for breakpoint adjustments, and the recalculation of disk diffusion QC ranges. Clinical laboratories should exclusively use MIC methods to assist the therapeutic application of colistin or polymyxin B until disk diffusion test modifications are sanctioned and published by the NCCLS.


* Corresponding author. Present address: 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371.


Journal of Clinical Microbiology, January 2001, p. 183-190, Vol. 39, No. 1
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.1.183-190.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • El Solh, A. A., Alhajhusain, A. (2009). Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 64: 229-238 [Abstract] [Full Text]  
  • Hodgson, K., Engler, C., Govan, B., Ketheesan, N., Norton, R. (2009). Comparison of Routine Bench and Molecular Diagnostic Methods in Identification of Burkholderia pseudomallei. J. Clin. Microbiol. 47: 1578-1580 [Abstract] [Full Text]  
  • Lu, P.-L., Doumith, M., Livermore, D. M., Chen, T.-P., Woodford, N. (2009). Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother 63: 641-647 [Abstract] [Full Text]  
  • Savini, V., Catavitello, C., Talia, M., Balbinot, A., Febbo, F., Pompilio, A., Di Bonaventura, G., Piccolomini, R., D'Antonio, D. (2009). Isolation of colistin-resistant Hafnia alvei. J Med Microbiol 58: 278-280 [Full Text]  
  • Capone, A., D'Arezzo, S., Visca, P., Petrosillo, N., on behalf of the Gruppo Romano Acinetobacter bauma, (2008). In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 62: 422-423 [Full Text]  
  • Landman, D., Georgescu, C., Martin, D. A., Quale, J. (2008). Polymyxins Revisited. Clin. Microbiol. Rev. 21: 449-465 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Mastoraki, A., Douka, E., Kriaras, I., Stravopodis, G., Saroglou, G., Geroulanos, S. (2008). Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units. Eur. J. Cardiothorac. Surg. 33: 1086-1090 [Abstract] [Full Text]  
  • Zavascki, A. P., Goldani, L. Z., Li, J., Nation, R. L. (2007). Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60: 1206-1215 [Abstract] [Full Text]  
  • Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 3471-3484 [Full Text]  
  • Warner, E., Oliver, J. D. (2007). Refined Medium for Direct Isolation of Vibrio vulnificus from Oyster Tissue and Seawater. Appl. Environ. Microbiol. 73: 3098-3100 [Abstract] [Full Text]  
  • Arnold, T. M., Forrest, G. N., Messmer, K. J. (2007). Polymyxin antibiotics for gram-negative infections. Am J Health Syst Pharm 64: 819-826 [Abstract] [Full Text]  
  • Tan, T. Y., Ng, L. S. Y. (2006). Comparison of three standardized disc susceptibility testing methods for colistin. J Antimicrob Chemother 58: 864-867 [Abstract] [Full Text]  
  • Lolans, K., Rice, T. W., Munoz-Price, L. S., Quinn, J. P. (2006). Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40.. Antimicrob. Agents Chemother. 50: 2941-2945 [Abstract] [Full Text]  
  • Souli, M., Kontopidou, F. V., Koratzanis, E., Antoniadou, A., Giannitsioti, E., Evangelopoulou, P., Kannavaki, S., Giamarellou, H. (2006). In Vitro Activity of Tigecycline against Multiple-Drug-Resistant, Including Pan-Resistant, Gram-Negative and Gram-Positive Clinical Isolates from Greek Hospitals.. Antimicrob. Agents Chemother. 50: 3166-3169 [Abstract] [Full Text]  
  • Zavascki, A. P., Barth, A. L., Goncalves, A. L. S., Moro, A. L. D., Fernandes, J. F., Martins, A. F., Ramos, F., Goldani, L. Z. (2006). The influence of metallo-{beta}-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 58: 387-392 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Falagas, M. E., Kasiakou, S. K., Tsiodras, S., Michalopoulos, A. (2006). The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.. Clin Med Res 4: 138-146 [Abstract] [Full Text]  
  • Nouer, S. A., Nucci, M., de-Oliveira, M. P., Pellegrino, F. L. P. C., Moreira, B. M. (2005). Risk Factors for Acquisition of Multidrug-Resistant Pseudomonas aeruginosa Producing SPM Metallo-{beta}-Lactamase. Antimicrob. Agents Chemother. 49: 3663-3667 [Abstract] [Full Text]  
  • Morosini, M. I., Garcia-Castillo, M., Loza, E., Perez-Vazquez, M., Baquero, F., Canton, R. (2005). Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips. J. Clin. Microbiol. 43: 4480-4485 [Abstract] [Full Text]  
  • Bratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., Landman, D. (2005). Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56: 128-132 [Abstract] [Full Text]  
  • Landman, D., Bratu, S., Alam, M., Quale, J. (2005). Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 55: 954-957 [Abstract] [Full Text]  
  • Quinn, A. L, Parada, J. P, Belmares, J., O'Keefe, J P. (2005). Intrathecal Colistin and Sterilization of Resistant Pseudomonas aeruginosa Shunt Infection. The Annals of Pharmacotherapy 39: 949-952 [Abstract] [Full Text]  
  • Arroyo, L. A., Garcia-Curiel, A., Pachon-Ibanez, M. E., Llanos, A. C., Ruiz, M., Pachon, J., Aznar, J. (2005). Reliability of the E-Test Method for Detection of Colistin Resistance in Clinical Isolates of Acinetobacter baumannii. J. Clin. Microbiol. 43: 903-905 [Abstract] [Full Text]  
  • Jones, R. N., Anderegg, T. R., Swenson, J. M., The Quality Control Working Group, (2005). Quality Control Guidelines for Testing Gram-Negative Control Strains with Polymyxin B and Colistin (Polymyxin E) by Standardized Methods. J. Clin. Microbiol. 43: 925-927 [Abstract] [Full Text]  
  • Riccio, M. L., Pallecchi, L., Docquier, J.-D., Cresti, S., Catania, M. R., Pagani, L., Lagatolla, C., Cornaglia, G., Fontana, R., Rossolini, G. M. (2005). Clonal Relatedness and Conserved Integron Structures in Epidemiologically Unrelated Pseudomonas aeruginosa Strains Producing the VIM-1 Metallo-{beta}-Lactamase from Different Italian Hospitals. Antimicrob. Agents Chemother. 49: 104-110 [Abstract] [Full Text]  
  • Swenson, J. M., Killgore, G. E., Tenover, F. C. (2004). Antimicrobial Susceptibility Testing of Acinetobacter spp. by NCCLS Broth Microdilution and Disk Diffusion Methods. J. Clin. Microbiol. 42: 5102-5108 [Abstract] [Full Text]  
  • Sobieszczyk, M. E., Furuya, E. Y., Hay, C. M., Pancholi, P., Della-Latta, P., Hammer, S. M., Kubin, C. J. (2004). Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54: 566-569 [Abstract] [Full Text]  
  • O'Carroll, M.R., Syrmis, M.W., Wainwright, C.E., Greer, R.M., Mitchell, P., Coulter, C., Sloots, T.P., Nissen, M.D., Bell, S.C. (2004). Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 24: 101-106 [Abstract] [Full Text]  
  • Poirel, L., Lebessi, E., Castro, M., Fevre, C., Foustoukou, M., Nordmann, P. (2004). Nosocomial Outbreak of Extended-Spectrum {beta}-Lactamase SHV-5-Producing Isolates of Pseudomonas aeruginosa in Athens, Greece. Antimicrob. Agents Chemother. 48: 2277-2279 [Abstract] [Full Text]  
  • Nicodemo, A. C., Araujo, M. R. E., Ruiz, A. S., Gales, A. C. (2004). In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother 53: 604-608 [Abstract] [Full Text]  
  • Mutnick, A. H, Kirby, J. T, Jones, R. N (2003). CANCER Resistance Surveillance Program: Initial Results from Hematology-Oncology Centers in North America. The Annals of Pharmacotherapy 37: 47-56 [Abstract] [Full Text]  
  • Pellegrino, F. L. P. C., Teixeira, L. M., Carvalho, M. d. G. S., Aranha Nouer, S., Pinto de Oliveira, M., Mello Sampaio, J. L., D'Avila Freitas, A., Ferreira, A. L. P., Amorim, E. d. L. T., Riley, L. W., Moreira, B. M. (2002). Occurrence of a Multidrug-Resistant Pseudomonas aeruginosa Clone in Different Hospitals in Rio de Janeiro, Brazil. J. Clin. Microbiol. 40: 2420-2424 [Abstract] [Full Text]  
  • Schulin, T. (2002). In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 49: 403-406 [Abstract] [Full Text]  
  • Saiman, L., Chen, Y., Tabibi, S., San Gabriel, P., Zhou, J., Liu, Z., Lai, L., Whittier, S. (2001). Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. J. Clin. Microbiol. 39: 3942-3945 [Abstract] [Full Text]